- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
220
of these compounds (Holven et al., 2006). Evidence that XFS is accompanied by low-grade inflammation has been presented (Ovodenko et al., 2007).
Lysyl oxidase. Lysyl oxidase in vascular endothelia is inhibited by high concentrations of homocysteine. This downregulation impairs the endothelial barrier function and could be involved in homocysteine-induced endothelial dysfunction (Raposo et al., 2004). Endothelial dysfunction induced by tumor necrosis factor-alpha (TNF-a) is also associated with a decrease of lysyl oxidase expression or activity (Rodrı´guez et al., 2007). Hyperhomocysteinemia in animals is associated with disruption of the elastic fiber component of the extracellular matrix, with resulting vascular complications (Starcher and Hill, 2005).
Transforming growth factor-b1 (TGF-b1) also interacts with lysyl oxidase to influence the formation of elastic tissue (Oleggini et al., 2007), and levels of TGF-b1 are significantly elevated in the aqueous humor of eyes with XFS and are believed to be both responsible for overproduction of extracellular matrix and an important causative factor for the production of XFM (Schlo¨tzerSchrehardt et al., 1999). TGFb-1 and b-2 contribute to conjunctival scarring after filtering surgery (Kottler et al., 2005). Modification of TGF-b1 activity may improve both the disease itself and the surgical treatment necessitated by it.
Our eventual goal is to prevent the development of XFM, thus effectively curing this disease. A treatment which would eliminate the formation of XFM or depolymerize it once formed should be a prime goal. Possible approaches include finding a means to prevent it from aggregating initially, prevent it from cross-linking, disaggregating the fibrils, and depolymerizing the microfibrils.
Interactions between lysyl oxidase, homocysteine, TGF-b1, and their effect upon elastic tissue in XFS require clarification. How do the different polymorphisms of the LOXL1 gene affect these interactions and alter elastogenesis? Will mutations in LOXL1 be discovered? Different mutations may lead to greater or lesser disease severity. In the future, will we be able to modulate LOXL1
gene activity to alter the course of XFS? These and other questions are now open to further exploration in an attempt to manage this very common and severe glaucoma.
References
Aasved, H. (1969) The geographical distribution of fibrillopathia epitheliocapsularis. Acta Ophthalmol., 47: 792–810.
Altintas, O., Maral, H., Yuksel, N., Karabas, V.L., Dillioglugil, M.O. and Caglar, Y. (2005) Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol., 243: 677–683.
Andrikopoulos, G.K., Mela, E.K., Georgakopoulos, C.D., et al. (2007) Pseudoexfoliation syndrome prevalence in Greek patients with cataract and its association to glaucoma and coronary artery disease. Eye, Epub Oct 12.
Aragon-Martin, J.A., Ritch, R., Liebmann, J., O’Brien, C., Blaaow, K., Mercieca, F., Spiteri, A., Cobb, C., Damji, K., Tarkkanen, A., Rezaie, T., Child, A. and Sarfarazi, M. (2008) Evaluation of LOXL1 gene polymorphisms in exfoliation syndrome and exfoliation glaucoma. Mol. Vis., 14: 533–541.
Aydogan Ozkan, B., Yuksel, N., Keskin, G., et al. (2006) Homocysteine levels in plasma and sensorineural hearing loss in patients with pseudoexfoliation syndrome. Eur. J. Ophthalmol., 16: 542–547.
Barkana, Y., Anis, S., Liebmann, J.M., Tello, C. and Ritch, R. (2006) Intraocular pressure monitoring outside of normal office hours in patients with glaucoma is clinically useful. Arch. Ophthalmol., 124: 793–799.
Becker, B. (1995) Does hyposecretion of aqueous humor damage the trabecular meshwork? (editorial). J. Glaucoma, 4: 303–305.
Bedri, A. and Alemu, B. (1999) Pseudoexfoliation syndrome in Ethiopian glaucoma patients. East Afr. Med. J., 76: 278–280.
Bengtsson, B. and Heijl, A. (2005) A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J. Glaucoma, 14: 135–138.
Bill, A., Lu¨tjen-Drecoll, E. and Svedbergh, B. (1980) Effects of intracameral Na2 EDTA and EGTA on aqueous outflow routes in the monkey eye. Invest. Ophthalmol. Vis. Sci., 19: 492–504.
Bleich, S., Roedl, J., Von Ahsen, N., Schlo¨tzer-Schrehardt, U., Reulbach, U., Beck, G., Kruse, F.E., Naumann, G.O.H., Kornhuber, J. and Junemann, A.G.M. (2004) Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am. J. Ophthalmol., 138: 162–164.
Cahill, M., Early, A., Stack, S., Blayney, A.W. and Eustace, P. (2002) Pseudoexfoliation and sensorineural hearing loss. Eye, 16: 261–266.
Colin, J., Le Gall, G., Le Jeune, B., et al. (1988) The prevalence of exfoliation syndrome in different areas of France. Acta Ophthalmol., 66(Suppl 184): 86–89.
Cursiefen, C., Hammer, T., Ku¨chle, M., Naumann, G.O.H. and Schlo¨tzer-Schrehardt, U. (2001) Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. Acta Ophthalmol. Scand., 79: 476–478.
Drolsum, L. (2003) Deep sclerectomy in patients with capsular glaucoma. Acta Ophthalmol. Scand., 81: 567–572.
Drolsum, L. (2006) Longterm follow-up after deep sclerectomy in patients with pseudoexfoliative glaucoma. Arch. Ophthalmol. Scand., 84: 502–506.
Ethier, C.R., Read, A.T. and Chan, D.W. (2006) Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest. Ophthalmol. Vis. Sci., 47: 1991–1998.
Fingert, J.H., Alward, W.L., Kwon, Y.H., Wang, K., Streb, L.M., Sheffield, V.C. and Stone, E.M. (2007). LOXL1 mutations are associated with exfoliation syndrome in patients from the Midwestern United States. Am. J. Ophthalmol., 144: 974–975.
Gilad, G.M., Kagan, H.M. and Gilad, V.H. (2005) Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer’s disease brain. Neurosci. Lett., 376: 210–214.
Gillies, W.E. (1977) Trabeculotomy in pseudoexfoliation of the lens capsule. Br. J. Ophthalmol., 61: 297–305.
Gracner, T. (2002) Intraocular pressure response of capsular glaucoma and primary open angle glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial. Eur. J. Ophthalmol., 12: 287–292.
Gradle, H.S. and Sugar, H.S. (1947) Glaucoma capsulare. Am. J. Ophthalmol., 30: 12–19.
Hagadus, R.J., Wandel, T., Ritch, R., et al. (1989) Pseudoexfoliation in patients with Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci., 30(Suppl): p. 27.
Hammer, T., Schlo¨tzer-Schrehardt, U. and Naumann, G.O.H. (2001) Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study. Arch. Ophthalmol., 119: 1023–1031.
Harasymowicz, P.J., Papamatheakis, D.G., Latina, M., de Leon, M., Lesk, M.R. and Damji, K.F. (2005) Selective laser trabeculoplasty (SLT) complicated by intraocular pressure elevation in eyes with heavily pigmented trabecular meshworks. Am. J. Ophthalmol., 139(6): 1110–1113.
Harju, M. and Vesti, E. (2001) Blood flow of the optic nerve head and peripapillary retina in exfoliation syndrome with unilateral glaucoma or ocular hypertension. Graefes Arch. Clin. Exp. Ophthalmol., 239: 271–277.
Hayashi, H., Gotoh, N. and Ueda, Y. et al., (2008) Lysyl oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population. Am. J. Ophthalmol., Jan 15 Epub ahead of print.
Hewitt, A.W. et al., (2007) Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. Hum. Mol. Genet., Nov. 23 Epub ahead of print.
221
Ho, S.L., Dogar, G.F., Wang, J., et al. (2005) Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br. J. Ophthalmol., 89: 169–173.
Hollo´, G., Lakatos, P. and Farkas, K. (1998) Cold pressor test and plasma endothelin-1 concentration in primary openangle glaucoma and capsular glaucoma. J. Glaucoma, 7: 105–110.
Holven, K.B., Halvorsen, B., Schulz, H., et al. (2006) Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand. J. Clin. Lab. Invest., 66: 45–54.
Honjo, M., Tanihara, H., Inatani, M., et al. (1998) Phacoemulsification, intraocular lens implantation, and trabeculotomy to treat pseudoexfoliation syndrome. J. Cataract Refract. Surg., 24: 781–786.
Horns, D.J.,, et al. (1983) Argon laser trabeculoplasty for open angle glaucoma: a retrospective study of 380 eyes. Trans. Ophthalmol. Soc. UK, 103: 288–294.
Irkec, M. (2006) Exfoliation and carotid stiffness (editorial). Br. J. Ophthalmol., 90: 529–530.
Jacobi, P.C., Dietlein, T.S. and Krieglstein, G.K. (1998) Bimanual trabecular aspiration in pseudoexfoliation glaucoma — an alternative in nonfiltering glaucoma surgery. Ophthalmology, 105: 886–894.
Jones, W., White, R.E. and Magnus, D.E. (1992) Increased occurrence of exfoliation in the male, Spanish American population of New Mexico. J. Am. Optom. Assoc., 63: 643–648.
Katula, K.S., Heinloth, A.N. and Paules, R.S. (2007) Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J. Nutr. Biochem., 18: 541–552.
Kaufman, P.L. and Ba´ra´ny, E.H. (1977) Cytochalasin B reversibly increases outflow facility in the eye of the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci., 16: 47–53.
Kiland, J.A., Miller, C.L., Kim, C.B., et al. (2006) Effect of H-7 and Lat-B on retinal physiology. Curr. Eye Res., 31: 441–455.
Koliakos, G.G., Konstas, A.G.P., Schlo¨tzer-Schrehardt, U., et al. (2002) Ascorbic acid concentration is reduced in the aqueous humor of patients with exfoliation syndrome. Am. J. Ophthalmol., 134: 879–883.
Koliakos, G.G., Konstas, A.G.P., Schlo¨tzer-Schrehardt, U., et al. (2003) 8-Isoprostaglandin F2a and ascorbic acid concentration in the aqueous humour of patients with exfoliation syndrome. Br. J. Ophthalmol., 87: 353–356.
Koliakos, G.G., Schlo¨tzer-Schrehardt, U., Konstas, A.G., Bufidis, T., Georgiadis, N. and Dimitriadou, A. (2001) Transforming and insulin like growth factor in the aqueous humor of patients with exfoliation syndrome. Graefes Arch. Clin. Exp. Ophthalmol., 239: 482–487.
Konstas, A.G.P., Hollo´, G., Astakhov, Y.S., et al. (2004) Factors associated with long-term progression or stability in exfoliation glaucoma. Arch. Ophthalmol., 122: 29–33.
Konstas, A.G.P., Hollo´, G., Irkec, M., Tsironi, S., Durukan, I., Goldenfeld, M. and Melamed, S. (2007b) Diurnal IOP
222
control with bimatoprost vs latanoprost in exfoliative glaucoma: a crossover observer-masked 3-center study. Br. J. Ophthalmol., 91: 757–760.
Konstas, A.G.P., Koliakos, G.G., Karabatsas, C.H., et al. (2006a) Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Exp. Eye Res., 82: 319–322.
Konstas, A.G.P., Kozobolis, V.P., Katsimpris, I.E., et al. (2007a) Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology, 114: 653–657.
Konstas, A.G.P., Topouzis, F., Leliopoulou, O., et al. (2006b) 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology, 113: 761–765.
Kottler, U.B., Ju¨nemann, A.G., Aigner, T., Zenkel, M., Rummelt, C. and Schlo¨tzer-Schrehardt, U. (2005) Comparative effects of TGF-beta1 and TGF-beta2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon’s capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp. Eye Res., 80: 121–134.
Kozart, D.M. and Yanoff, M. (1982) Intraocular pressure status in 100 consecutive patients with exfoliation syndrome. Ophthalmology, 89: 214–218.
Kozobolis, V.P., Papatzanaki, M., Vlachonikolis, I.G., Pallikaris, I.G. and Tsambarlakis, I.G. (1997) Epidemiology of pseudoexfoliation in the island of Crete (Greece). Acta Ophthalmol., 75: 726–729.
Kuhlenbaumer, G., Friedrichs, F., Kis, B., et al. (2007) Association between single nucleotide polymorphisms in the lysyl oxidase-like 1 gene and spontaneous cervical artery dissection. Cerebrovasc. Dis., 24: 343–348.
Laatikainen, L. (1971) Fluorescein angiographic studies of the peripapillary and perilimbal regions in simple, capsular and low-tension glaucoma. Acta Ophthalmol., III(Suppl.): 3–83.
Leibovitch, I., Kurtz, S., Shemesh, G., et al. (2003) Hyperhomocystinemia in pseudoexfoliation glaucoma. J. Glaucoma, 12: 36–39.
Leske, M.C., Heijl, A., Hussein, M., et al. (2003) Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch. Ophthalmol., 121: 48–56.
Lewis, C.M., Smith, A.K. and Kamen, B.A. (1998) Receptormediated folate uptake is positively regulated by disruption of the actin cytoskeleton. Cancer Res., 15: 2952–2956.
Linne´r, E., Popovic, V., Gottfries, C.G., et al. (2001) The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer’s type. Acta Ophthalmol. Scand., 79: 283–285.
Liu, X., Zhao, Y., Gao, J., et al. (2004) Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat. Genet., 36: 178–182.
Lobo, A., Naso, A., Arheart, K., et al. (1999) Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am. J. Cardiol., 83: 821–825.
Masse´, P.G., Yamauchi, M., Mahuren, J.D., et al. (1995) Connective tissue integrity is lost in vitamin B-6-deficient chicks. J. Nutr., 125: 26–34.
Merrill, A.H. and Henderson, M. (1987) Diseases associated with defects in vitamin B6 metabolism or utilization. Annu. Rev. Nutr., 7: 137–156.
Mitchell, P., Wang, J.J. and Hourihan, F. (1999) The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. Arch. Ophthalmol., 117: 1319–1328.
Mitchell, P., Wang, J.J. and Smith, W. (1997) Association of pseudoexfoliation with increased vascular risk. Am. J. Ophthalmol., 124: 685–687.
Moreno Montan˜e´s, J., Alcolea Paredes, A. and Campos Garcı´a, S. (1989) Prevalence of pseudoexfoliation syndrome in the northwest of Spain. Acta Ophthalmol., 67: 383–385.
Naumann, G.O.H., Schlo¨tzer-Schrehardt, U. and Ku¨chle, M. (1998) Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology, 105: 951–968.
Odberg, T. and Sandvik, L. (1999) The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open-angle glaucoma. Acta Ophthalmol., 77: 176–181.
Okka, M., Tian, B. and Kaufman, P.L. (2004) Effect of lowdose latrunculin B on anterior segment physiologic features in the monkey. Arch. Ophthalmol., 122: 1482–1488.
Oleggini, R., Gastaldo, N. and Di Donato, A. (2007) Regulation of elastin promoter by lysyl oxidase and growth factors: cross control of lysyl oxidase on TGF-beta1 effects. Matrix Biol., 26: 494–505.
Ovodenko, B., Rostagno, A., Neubert, T.A., et al. (2007) Proteomic analysis of lenticular exfoliation deposits. Invest. Ophthalmol. Vis. Sci., 48: 1447–1457.
Peterson, J.A., Tian, B., Geiger, B. and Kaufman, P.L. (2000) Effect of latrunculin-B on outflow facility in monkeys. Exp. Eye Res., 70: 307–314.
Prince, A.M. and Ritch, R. (1986) Clinical signs of the pseudoexfoliation syndrome. Ophthalmology, 93: 803–807.
Prince, A.M., Streeten, B.W., Ritch, R., Dark, A.J. and Sperling, M. (1987) Preclinical diagnosis of pseudoexfoliation syndrome. Arch. Ophthalmol., 105: 1076–1082.
Puska, P., Vesti, E., Tomita, G., Ishida, K. and Raitta, C. (1999) Optic disc changes in normotensive persons with unilateral exfoliation syndrome: a 3-year follow-up study. Graefes Arch. Clin. Exp. Ophthalmol., 237: 457–462.
Puustja¨rvi, T., Blomster, H., Kontkanen, M., et al. (2004) Plasma and aqueous humour levels of homocysteine in exfoliation syndrome. Graefe’s Arch. Clin. Exp. Ophthalmol., 242: 749–754.
Raposo, B., Rodriguez, C., Martı´nez-Gonza´les, J. and Badimon, L. (2004) High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis, 177: 1–8.
Rekonen, P., Kannisto, T., Puustja¨rvi, T., et al. (2006) Deep sclerectomy for the treatment of exfoliation and primary open-angle glaucoma. Arch. Ophthalmol. Scand., 84: 507–511.
Repo, L.P., Suhonen, M.T., Tera¨svirta, M.E. and Koivisto, J.K. (1995) Color Doppler imaging of the ophthalmic artery blood flow spectra of patients who have had a transient ischemic attack. Correlations with generalized iris transluminance and pseudoexfoliation syndrome. Ophthalmology, 102: 1199–1205.
Ringvold, A., Blika, S., Elsa˚s, T., et al. (1988) The middleNorway eye-screening study. I. Epidemiology of the pseudoexfoliation syndrome. Acta Ophthalmol., 66: 652–657.
Ritch, R. (1994) Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J. Glaucoma, 3: 176–178.
Ritch, R. and Podos, S.M. (1983) Laser trabeculoplasty in exfoliation syndrome. Bull. N.Y. Acad. Med., 59: 339–344.
Ritch, R. and Schlo¨tzer-Schrehardt, U. (2001) Exfoliation syndrome. Surv. Ophthalmol., 45: 265–315.
Ritch, R., Schlo¨tzer-Schrehardt, U. and Konstas, A.G.P. (2003) Why is glaucoma associated with exfoliation syndrome? Prog. Retinal Eye Res., 22: 253–275.
Rodrı´guez, C., Alcudia, J.F. and Martı´nez-Gonza´lez, J. et al., 2007. Lysyl oxidase (LOX) down-regulation by TNFalpha: a new mechanism underlying TNFalpha-induced endothelial dysfunction. Atherosclerosis, Epub ahead of print.
Roedl, J.B., Bleich, S., Reulbach, U., et al. (2007a) Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J. Glaucoma, 16: 234–239.
Roedl, J.B., Bleich, S., Reulbach, U., et al. (2007b) Vitamin deficiency and hyperhomocysteinemia in pseudoexfoliation glaucoma. J. Neural. Transm., 114: 571–575.
Ro¨nkko¨, S., Rekonen, P., Kaarniranta, K., et al. (2007) Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefe’s Arch. Clin. Exp. Ophthalmol., 245: 697–704.
Roth, M. and Epstein, D.L. (1980) Exfoliation syndrome. Am. J. Ophthalmol., 89: 477–486.
Saatci, O.A., Ferliel, S.T., Ferliel, M., et al. (1999) Pseudoexfoliation and glaucoma in eyes with retinal vein occlusion. Int. Ophthalmol., 23: 75–78.
Sabanay, I., Tian, B., Gabelt, B.A.T., et al. (2006) Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys. Exp. Eye Res., 82: 236–246.
Schlo¨tzer-Schrehardt, U., Koca, M.R., Naumann, G.O.H. and Volkholz, H. (1992) Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch. Ophthalmol., 110: 1752–1756.
Schlo¨tzer-Schrehardt, U., Ku¨chle, M., Dorfler, S. and Naumann, G.O.H. (1993) Pseudoexfoliative material in the eyelid skin of pseudoexfoliation-suspect patients: a clinicohistopathological correlation. German J. Ophthalmol., 2: 51–60.
Schlo¨tzer-Schrehardt, U., Ku¨chle, M., Rummelt, C. and Naumann, G.O.H. (1999) Role of transforming growth factor-b and its latent form binding protein in pseudoexfoliation syndrome. Invest. Ophthalmol. Vis. Sci., 40: p. S278.
223
Schlo¨tzer-Schrehardt, U., Lommatzsch, J., Ku¨chle, M., Konstas, A.G.P. and Naumann, G.O.H. (2003) Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., 44: 1117–1125.
Schlo¨tzer-Schrehardt, U. and Naumann, G.O.H. (2006) Ocular and systemic pseudoexfoliation syndrome. Am. J. Ophthalmol., 141: 921–937.
Scullica, L., Buceti, R., Castagna, I., Ferreri, G. and Trombetta, C.J. (1993) Functional aspects of pseudoexfoliation: physiopathological features. New Trends Ophthalmol., 8: 163–168.
Selhub, J. (2006) The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J. Nutr., 136(6 Suppl.): 1726S–1730S.
Shaban, R.I. and Asfour, W.M. (2004) Ocular pseudoexfoliation associated with hearing loss. Saudi Med. J., 25: 1254–1257.
Shakya, S., Koirala, S. and Karmacharya, P.C.D. (2004) Pseudoexfoliation syndrome in Nepal: a hospital-based retrospective study. Asia-Pacific J. Ophthalmol., 16: 13–16.
Shimizu, K., Kimura, Y. and Aoki, K. (1988) Prevalence of exfoliation syndrome in the Japanese. Acta Ophthalmol., 66(Suppl 184): 112–115.
Sibour, G., Finazzo, C. and Boles Carenini, A. (1997) Monolateral pseudoexfoliatio capsulae: a study of choroidal blood flow. Acta Ophthalmol. Scand., 75(Suppl 224): 13–14.
Starcher, B. and Hill, C.H. (2005) Elastin defects in the lungs of avian and murine models of homocysteinemia. Exp. Lung Res., 31: 873–885.
Streeten, B.W., Gibson, S.A. and Dark, A.J. (1986) Pseudoexfoliative material contains an elastic microfibrillarassociated glycoprotein. Trans. Am. Ophthalmol. Soc., 84: 304–320.
Streeten, B.W., Li, Z.Y., Wallace, R.N., Eagle, R.C.J. and Keshgegian, A.A. (1992) Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch. Ophthalmol., 110: 1757–1762.
Tanihara, H., Negi, A., Akimoto, M., Terauchi, H., Okudaira, A., Kozaki, J., Takeuchi, A. and Nagata, M. (1993) Surgical effect of trabeculotomy ab externo on adult eyes with primary open angle glaucoma and pseudoexfoliation syndrome. Arch. Ophthalmol., 111: 1653–1661.
Thorliefsson, G., Magnusson, K.P., Sulem, P., et al. (2007) Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science, 317: 1397–1400.
Tian, B., Kaufman, P.L., Volberg, T., Gabelt, B.T. and Geiger, B. (1998) H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch. Ophthalmol., 116: 633–643.
Tian, B., Gabelt, B.T., Geiger, B. and Kaufman, P.L. (1999) Combined effects of H-7 and cytochalasin B on outflow facility in monkeys. Exp. Eye Res., 68: 649–655.
Vessani, R.M., Liebmann, J.M., Jofe, M. and Ritch, R. (2003) Plasma homocysteine is elevated in patients with exfoliation syndrome. Am. J. Ophthalmol., 136: 41–46.
224
Visontai, Z., Merisch, B.M., Kollai, M. and Hollo, G. (2006) Increase of carotid artery stiffness and decrease of baroreflex sensitivity in exfoliation syndrome and glaucoma. Br. J. Ophthalmol., 360–367: p. 90.
Yilmaz, A., Adiguzel, U., Tamer, L., et al. (2005) Serum oxidant/antioxidant balance in exfoliation syndrome. Clin. Experiment. Ophthalmol., 33: 63–66.
Yu¨ksel, N., Anik, Y., Kilic, A., Karabas, V., Demirci, A. and Caglar, Y. (2006) Cerebrovascular blood flow velocities in pseudoexfoliation. Graefes Arch. Clin. Exp. Ophthalmol., 244: 316–321.
Yu¨ksel, N., Karabas, V.L., Arslan, A., et al. (2001) Ocular hemodynamics in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Ophthalmology, 108: 1043–1049.
Zee, R.Y., Mora, S., et al. (2007) Homocysteine, 5,10-methyl- enetetrahydrofolate reductase 677CWT polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin. Chem., 53: 845–851.
Zenkel, M., Kruse, F.E., Ju¨nemann, A.G., Naumann, G.O.H. and Schlo¨tzer-Schrehardt, U. (2006) Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest. Ophthalmol. Vis. Sci., 47: 1982–1990.
Zenkel, M., Po¨schl, E., von der Mark, K., Carmen HofmannRummelt, C., Naumann, G.O.H., Kruse, F.E. and Schlo¨tzerSchrehardt, U. (2005) Differential gene expression in pseudoexfoliation syndrome. Invest. Ophthalmol. Vis. Sci., 46: 3742–3752.